

New York State Medicaid Drug Utilization Review (DUR) Board Meeting Summary for December 15, 2022

The Medicaid DUR Board met on Thursday, December 15, 2022, from 10:00am to 2:00pm.

The meeting was offered for public viewing by way of:

- Empire State Plaza, Concourse Level, Albany, NY
- SUNY at Buffalo, School of Pharmacy, Buffalo, NY
- SUNY Global Center, New York, NY
- St. John Fisher University, Rochester, NY
- Live webcast

Lisa Anzisi

Meeting Documents Meeting Transcript Meeting Webcast

A. Welcome and Introductions

Department of Health (DOH)

Douglas Fish – Medicaid Medical Director and DUR Board Chairperson Kimberly Leonard – Medicaid Pharmacy Director Monica Toohey Anthony Merola Robert Correia Jacqueline Sexton

DUR Board Members Participating Location

Marla Eglowstein Empire State Plaza, Concourse Level, Albany, NY SUNY Global Center, New York, NY Empire State Plaza, Concourse Level, Albany, NY

SUNY Global Center, New York, NY

James Hopsicker Empire State Plaza, Concourse Level, Albany, NY Empire State Plaza, Concourse Level, Albany, NY

Jill Lavigne St. John Fisher University, Rochester, NY

Peter Lopatka Empire State Plaza, Concourse Level, Albany, NY Michael Pasquarella Empire State Plaza, Concourse Level, Albany, NY Empire State Plaza, Concourse Level, Albany, NY

Asa Radix SUNY Global Center, New York, NY

Tara Thomas Empire State Plaza, Concourse Level, Albany, NY Jamie Wooldridge SUNY at Buffalo, School of Pharmacy, Buffalo, NY

SUNY at Buffalo – School of Pharmacy and Pharmaceutical Sciences

Holly Coe Irene Reilly Barbara Rogler Alexia Sroka

B. Public Comment Period

The following speakers provided public comment to the DUR Board:

| <u>Name</u> | Organization/Affiliation | Agenda Item |
|------------------------------------------|----------------------------|----------------------|
| Rae Ann Maxwell Denise Cody | Biogen Patient Advocate | Spinraza Spinraza |
| Kathleen Maignan | Genentech | Evrysdi |
| Kathleen Maignan | Genentech | Ocrevus |
| Biran Patel | Bluebird Bio | Zynteglo |
| Craig Butler | Cooley's Anemia Foundation | Zynteglo |
| Craig Butler presenting for Eileen Scott | Patient Advocate | Zynteglo |

C. Drug Utilization Review (DUR)

The DUR Board reviewed the drugs listed below. The DOH's recommendations to the DUR

Board, including any DUR Board modifications (if noted), are as follows:

| Recommendations | Commissioner's Final Determinations |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| 1. Betibeglogene autotemcel (Zynteglo) a) The patient is less than or equal to (≤) 50 years of age. If the patient is less than (<) 5 years of age, the patient weight must be greater than or equal to (≥) 6 kg. b) The patient has a diagnosis of transfusion-dependent beta- thalassemia. c) The patient is a candidate for allogeneic hematopoietic cell transplantation, but ineligible due to the absence of a donor. Vote: In Favor 13 / Against 0 / Abstentions 0 | Approved as Recommended |
| Nusinersen (Spinraza) and Risdiplam (Evrysdi) The patient must not have advanced disease (e.g., complete limb paralysis or permanent ventilation dependence). Vote: In Favor 13 / Against 0 / Abstentions 0 | Approved as Recommended |

3. Ocrelizumab (Ocrevus)

Step Therapy:

Trial of an agent subject to the Preferred Drug Program Multiple Sclerosis Agents therapeutic class.

Exception for patients with a diagnosis of primary progressive multiple sclerosis (PPMS) who are ambulatory and have documented inflammatory activity.

The DUR Board did not vote on this topic. The DUR Board requested additional utilization data inclusive of other agents indicated for Multiple Sclerosis as well as for drugs subject to the NYRx Preferred Drug Program.

Not Applicable

D. Pharmacy Program Updates

The DUR Board was provided updates on:

- 1. Hepatitis C Virus Utilization of Direct Acting Antivirals
- 2. Medicaid Prescriber Education Program MPEP

E. Final Comments and Adjournment

Meeting adjourned at 2:00pm

Contact information: DUR@health.ny.gov or 518-486-3209

Drug Utilization Review (DUR) (ny.gov)